Loading...
Loading...
Laboratorios Farmaceuticos Rovi, S.A./ADR
Laboratorios Farmaceuticos Rovi, S.A./ADR. Spoken Alpha tracks LRVIY's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks LRVIY's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LRVIY.
curl https://api.spokenalpha.com/v1/companies/LRVIY| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.28 | $2.71 | -15.8% | +3.8% | +4.1% |
| Q4 FY2026 | $2.40 | $2.63 | -8.8% | -5.8% | -8.5% |
| Q3 FY2026 | $2.47 | $2.84 | -13.0% | +0.7% | +1.6% |
| Q2 FY2026 | $2.37 | $2.82 | -16.0% | -6.4% | -7.2% |
| Q1 FY2025 | $2.55 | $2.77 | -8.0% | +2.5% | +2.5% |
| Q4 FY2025 | $2.78 | $2.82 | -1.4% | +1.8% | +1.8% |
| Q3 FY2025 | $2.44 | $2.75 | -11.1% | +3.9% | +1.5% |
| Q2 FY2025 | $2.56 | $2.91 | -12.0% | +2.4% | +3.5% |
| Q1 FY2024 | $2.53 | $2.96 | -14.5% | +3.4% | +3.8% |
| Q4 FY2024 | $2.37 | $2.72 | -13.0% | -1.4% | -3.3% |